Tally Health (TallyAge)
Celebrity scientist co-founder (David Sinclair); lowest single-test entry price among major players; supplement bundled with membership; strong waitlist/community (270,000+)
NOT CLEARED
No FDA clearance, registration, or CE marking found.
Key facts at a glance.
- Founded
- 2023
- Headquarters
- New York, NY, US
- Price range
- $229–$229
- Trustpilot
- 3.6 / 5 (36)
The real price over three years.
Total cost of ownership · 3yr
| Hardwareone-time | $229 |
| 3-year total | $229 |
What the device does.
- + ~850,000 CpG sites analyzed via cheek swab
- + Proprietary TallyAge clock (machine-learning model)
- + Co-founded by longevity researcher Dr. David Sinclair
- + Personalized supplement included with membership
- + Digital platform with lifestyle recommendations
- + Quarterly retesting cadence on membership plans
- + Non-invasive cheek swab collection
The trade-offs.
- + **David Sinclair celebrity-scientist co-founder** — Harvard longevity researcher, mainstream consumer brand recognition
- + $229 lowest single-test entry price among major bio-age players
- + 270,000+ stated waitlist / community size — strong consumer awareness signal
- + Personalized supplement bundled with membership
- + Non-invasive cheek swab collection (no blood draw required)
- + Quarterly retesting cadence on membership plans
- − **Cheek-swab methodology less validated than blood-based tests** — fewer measurable epigenetic signals in saliva/buccal cells
- − Proprietary TallyAge clock not independently peer-validated
- − Supplement-subscription model may feel like upselling
- − Trustpilot 3.6/5 with complaints about billing and cancellation
- − Very young company (launched 2023)
Mainstream health-curious consumers, David Sinclair followers, people wanting an easy-entry longevity test with lifestyle coaching
The long read.
§ Hands-on instrument testing pending. Based on published specifications and third-party data.
Overview
Tally Health (TallyAge) is the David-Sinclair-co-founded mainstream-accessible bio-age specialist — manufactured by Tally Health (founded 2023 in NYC), with structural credibility differentiator being co-founded by Dr. David Sinclair (Harvard longevity researcher, “Lifespan” book author, mainstream consumer-aware longevity figure). Combined with $229 lowest single-test entry price among major bio-age players, TallyAge targets mainstream health-curious consumers, David Sinclair followers, and entry-level longevity-tracking users wanting accessible-pricing bio-age with lifestyle coaching.
The structural value claim has genuine appeal for mass-market longevity-curious users: David Sinclair brand recognition is among the highest in consumer longevity; 270,000+ stated waitlist / community size reflects meaningful consumer awareness; cheek-swab collection eliminates blood-draw friction (especially for needle-averse buyers); quarterly retesting cadence on membership matches active-tracking protocols; bundled personalized supplement provides integrated longevity-stack workflow.
The structural editorial caveats are methodological + operational: cheek-swab methodology is less validated than blood-based tests (fewer measurable epigenetic signals in saliva/buccal cells vs blood — TruDiagnostic, Generation Lab, NOVOS use blood for higher signal quality), proprietary TallyAge clock not independently peer-validated (relies on celebrity-founder credibility + machine-learning model rather than published validation studies), supplement-subscription model creates upsell friction, Trustpilot 3.6/5 with complaints about billing and cancellation processes, and 2023-founded young company with limited longitudinal track record. For mainstream consumers prioritizing Sinclair-brand-recognition + lowest entry price + cheek-swab convenience willing to absorb methodological + operational caveats, Tally Health is structurally appropriate. For users wanting validated blood-based methodology, peer-reviewed published clocks, or stronger consumer-experience signal, alternatives are structurally better.
When Tally Health Makes Sense
Strong fit: David Sinclair followers; mainstream longevity-curious consumers; lowest single-test entry-price priority ($229); needle-averse buyers wanting cheek-swab; users in Sinclair-aligned supplement protocol ecosystem.
Weaker fit: Validated blood-based methodology preference (TruDiagnostic, NOVOS, Generation Lab); peer-reviewed published clocks (Horvath via myDNAge; PhenoAge via Elysium); supplement-cross-selling-averse buyers; established multi-decade track record preference.
3-Year Cost of Ownership
| Use case | Cost |
|---|---|
| Tally Health single test | ~$229 |
| Tally Health membership (quarterly + supplements) | varies by plan |
| 3-year ownership — single tests | ~$229-700 |
Compare: TruDiagnostic ($399-799), Elysium Index ($299 saliva), GlycanAge ($348), MyDNAge ($299), NOVOS Age ($349), Generation Lab ($490-500), Viome ($129-399).
Verdict: Conditional
Tally Health (TallyAge) earns a conditional verdict on the strength of its David Sinclair co-founder celebrity-scientist credibility (Harvard longevity researcher, “Lifespan” author, mainstream consumer awareness), $229 lowest single-test entry price among major bio-age players, 270,000+ stated waitlist / community awareness signal, personalized supplement bundled with membership, non-invasive cheek-swab collection eliminating blood-draw friction, and quarterly retesting cadence on membership plans — balanced against cheek-swab methodology less validated than blood-based tests, proprietary TallyAge clock not independently peer-validated, supplement-subscription upsell model, Trustpilot 3.6/5 with billing / cancellation complaints, and very young 2023-founded company.
For David Sinclair followers and mainstream consumers prioritizing accessible pricing + cheek-swab convenience, Tally Health is structurally appropriate. For users prioritizing validated blood-based methodology, peer-reviewed published clocks, supplement-cross-selling-averse positioning, or established track record, structurally better-matched alternatives exist.
Changelog
- 2026-05-07: Initial review published based on Tally Health (TallyAge) published specifications, David Sinclair co-founder positioning, cheek-swab collection methodology, Trustpilot 3.6/5 from 36 reviews, and aggregated user-report data.
What we'll measure on the bench.
- Protocol
- Methodology audit + 3-month paired retest
- Primary metric
- Δ biological age between paired tests
- Pass threshold
- <±2 yr drift across stable-lifestyle window
- Session shape
- 2 paired tests, 3 months apart
§ Bench session pending. Measured values will replace this panel as the protocol completes — see Plate VI · Methodology for the full testing rulebook.